|
|
Vaccine Detail
|
electroloading of mature dendritic cells with melanoma whole tumor cell lysate |
| Vaccine Information |
- Vaccine Name: electroloading of mature dendritic cells with melanoma whole tumor cell lysate
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007602
- Type: Dendritic Cell vaccine
- Status: Research
- Immunization Route: Intramuscular injection (i.m.)
- Description: A simple, widely used approach to generating multivalent cancer vaccines is to load tumor whole cell lysates into dendritic cells (DCs). Current DC vaccine manufacturing processes require co-incubation of tumor lysate antigens with immature DCs and their subsequent maturation (Wolfraim et al., 2013).
|
| Host Response |
|
Human Response
- Vaccine Immune Response Type: VO_0003057
- Immune Response: Electroloaded mature DCs were more potent in vitro, as judged by their ability to elicit significantly (p < 0.05) greater expansion of peptide antigen-specific CD8(+) T cells, than either lysate-electroloaded immature DCs or lysate-co-incubated immature DCs, both of which must be subsequently matured. Expanded CD8(+) T cells were functional as judged by their ability to produce IFN-γ upon antigen-specific re-stimulation (Wolfraim et al., 2013).
|
| References |
Wolfraim et al., 2013: Wolfraim LA, Takahara M, Viley AM, Shivakumar R, Nieda M, Maekawa R, Liu LN, Peshwa MV. Clinical scale electroloading of mature dendritic cells with melanoma whole tumor cell lysate is superior to conventional lysate co-incubation in triggering robust in vitro expansion of functional antigen-specific CTL. International immunopharmacology. 2013; 15(3); 488-497. [PubMed: 23474736].
|
|
